45.75
0.33%
-0.15
Pre-market:
46.20
0.45
+0.98%
Vera Therapeutics Inc stock is traded at $45.75, with a volume of 372.89K.
It is down -0.33% in the last 24 hours and up +11.15% over the past month.
Vera Therapeutics Inc is a clinical stage biotechnology company. It is focused on developing and commercializing transformative treatments for patients with serious immunological diseases. The company's product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection once weekly that blocks both B lymphocyte stimulator and a proliferation-inducing ligand, which stimulate B cells and plasma cells to produce autoantibodies contributing to certain autoimmune diseases.
See More
Previous Close:
$45.90
Open:
$46.11
24h Volume:
372.89K
Relative Volume:
0.51
Market Cap:
$2.93B
Revenue:
-
Net Income/Loss:
$-107.85M
P/E Ratio:
-13.62
EPS:
-3.36
Net Cash Flow:
$-106.82M
1W Performance:
-7.44%
1M Performance:
+11.15%
6M Performance:
+11.61%
1Y Performance:
+238.89%
Vera Therapeutics Inc Stock (VERA) Company Profile
Name
Vera Therapeutics Inc
Sector
Industry
Phone
650-770-0077
Address
2000 SIERRA POINT PARKWAY, SUITE 1200, BRISBANE
Compare VERA with other stocks
Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
---|---|---|---|---|---|---|
VERA | 45.75 | 2.93B | 0 | -107.85M | -106.82M | -3.36 |
VRTX | 451.23 | 115.74B | 10.63B | -479.80M | -1.35B | 13.33 |
REGN | 743.35 | 81.65B | 13.85B | 4.65B | 3.32B | 35.06 |
ARGX | 591.82 | 34.86B | 1.86B | -40.29M | -1.28B | -4.16 |
ALNY | 248.79 | 32.09B | 2.09B | -332.26M | 16.06M | -4.14 |
BNTX | 102.14 | 24.49B | 3.30B | -501.07M | 1.03B | 11.54 |
Vera Therapeutics Inc Stock (VERA) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Jan-25-24 | Initiated | Oppenheimer | Outperform |
Jan-08-24 | Initiated | Cantor Fitzgerald | Overweight |
Dec-18-23 | Initiated | Raymond James | Outperform |
Nov-10-23 | Upgrade | Jefferies | Hold → Buy |
Aug-16-23 | Initiated | Guggenheim | Buy |
Jan-04-23 | Downgrade | Jefferies | Buy → Hold |
Jan-04-23 | Downgrade | Wedbush | Outperform → Neutral |
Jul-12-22 | Initiated | JP Morgan | Overweight |
May-02-22 | Initiated | H.C. Wainwright | Buy |
Apr-19-22 | Initiated | Wedbush | Outperform |
View All
Vera Therapeutics Inc Stock (VERA) Latest News
GSA Capital Partners LLP Has $535,000 Holdings in Vera Therapeutics, Inc. (NASDAQ:VERA) - MarketBeat
Wall Street Analysts Think Vera Therapeutics (VERA) Could Surge 27.26%: Read This Before Placing a Bet - MSN
Calif. Biotech Firm Vera Taps Veteran Chief Legal Officer - Law360
First Turn Management LLC Increases Stock Holdings in Vera Therapeutics, Inc. (NASDAQ:VERA) - MarketBeat
Vera Therapeutics Appoints Jason S. Carter as Chief Legal Officer - GlobeNewswire
Vera Therapeutics Appoints Former Kite Pharma Legal Head as Chief Legal Officer | VERA Stock News - StockTitan
(VERA) Proactive Strategies - Stock Traders Daily
COMMODORE CAPITAL LP Adjusts Stake in Vera Therapeutics Inc - GuruFocus.com
Kynam Capital Management, LP Increases Stake in Vera Therapeutics Inc - GuruFocus.com
500: Something went wrong - Investing.com India
Vera Therapeutics stock soars to all-time high of $50.98 - Investing.com
Vera Therapeutics stock soars to all-time high of $50.98 By Investing.com - Investing.com Australia
Vera Therapeutics (NASDAQ:VERA) Reaches New 1-Year HighHere's What Happened - MarketBeat
FMR LLC Reduces Stake in Vera Therapeutics Inc - GuruFocus.com
Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Vera Therapeutics Partners with University of Michigan on the NEPTUNE Match Project and PIONEER Study - The Manila Times
Vera Therapeutics Awards $45.17 Stock Options to New Hires in Growth Push | VERA Stock News - StockTitan
Vera Therapeutics (NASDAQ:VERA) Posts Quarterly Earnings Results, Misses Expectations By $0.21 EPS - MarketBeat
Vera Therapeutics to Participate at Upcoming Investor Conferences - GlobeNewswire
Vera Therapeutics to Present at Two Major Healthcare Investor Conferences | VERA Stock News - StockTitan
Vera Therapeutics (NASDAQ:VERA) Price Target Raised to $38.00 - MarketBeat
Vera Therapeutics Advances in Autoimmune Treatment - TipRanks
Vera Therapeutics Provides Business Update and Reports Third Quarter 2024 Financial Results - The Manila Times
Vera Therapeutics, Inc. (NASDAQ:VERA) Given Average Rating of "Buy" by Brokerages - MarketBeat
JPMorgan Chase & Co. Boosts Vera Therapeutics (NASDAQ:VERA) Price Target to $75.00 - MarketBeat
Trading (VERA) With Integrated Risk Controls - Stock Traders Daily
Vera Therapeutics (NASDAQ:VERA) Shares Up 7.3%Here's Why - MarketBeat
Vera Therapeutics announces proposed public offering of class A common stock - MSN
Vera Therapeutics director Beth Seidenberg sells shares for $720,493 - Investing.com India
Vera Therapeutics director Beth Seidenberg sells shares for $720,493 By Investing.com - Investing.com Canada
Vera Therapeutics (NASDAQ:VERA) Sees Large Volume IncreaseHere's What Happened - MarketBeat
Vera Therapeutics (NASDAQ:VERA) PT Raised to $64.00 at Guggenheim - Defense World
Vera Therapeutics Announces Pricing of Public Offering of Class A Common Stock - GlobeNewswire
Vera Therapeutics (NASDAQ:VERA) Shares Gap DownHere's Why - MarketBeat
Vera Therapeutics price target raised to $64 from $56 at Guggenheim - Yahoo Finance
SEC Form 424B5 filed by Vera Therapeutics Inc. - Quantisnow
Vera Therapeutics Announces Proposed Public Offering of Class A Common Stock - The Manila Times
Vera Therapeutics (NASDAQ:VERA) Price Target Raised to $64.00 - MarketBeat
Vera Therapeutics' Atacicept Shows Sustained, Substantial Improvement In Kidney Function For Patients At Almost Two Years - AOL
Vera Therapeutics (NASDAQ:VERA) Shares Gap UpHere's What Happened - MarketBeat
Vera Therapeutics Shares Climb 14% on Positive Results in Kidney Disease Study - MarketWatch
PROCEPT BioRobotics Posts Strong Q3 Earnings, Joins Monte Rosa Therapeutics, EyePoint Pharmaceuticals And Other Big Stocks Moving Higher On Monday - Benzinga
Vera reports long-term atacicept data at Kidney Week 2024 - The Pharma Letter
VERAVera Therapeutics, Inc. Latest Stock News & Market Updates - StockTitan
Vera Therapeutics Announces 96-week eGFR Stabilization in ORIGIN Phase 2b Study of Atacicept in IgAN in a Late-Breaking Oral Presentation at the American Society of Nephrology Kidney Week 2024 - The Manila Times
Vera Therapeutics Announces 96-week eGFR Stabilization in - GlobeNewswire
Vera Therapeutics Inc Stock (VERA) Financials Data
Revenue
Net Income
Cash Flow
EPS
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):